Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVBP NASDAQ:COAG NASDAQ:HROW NYSEAMERICAN:LCTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$29.99-0.9%$27.10$16.10▼$32.14$1.40B1.41489,449 shs547,471 shsCOAGHemab Therapeutics$27.35-4.0%$0.00$23.00▼$36.61$1.28BN/A219,803 shs67,045 shsHROWHarrow$34.96-0.7%$36.03$27.17▼$54.85$1.30B0.28753,365 shs311,717 shsLCTXLineage Cell Therapeutics$1.28-4.1%$1.46$0.65▼$2.09$317.86M1.531.18 million shs687,909 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma0.00%+13.24%-2.64%+30.59%+42.78%COAGHemab Therapeutics0.00%+10.08%-16.18%+2,849,999,900.00%+2,849,999,900.00%HROWHarrow0.00%+6.70%-13.13%-34.30%+24.68%LCTXLineage Cell Therapeutics0.00%+2.31%-11.92%-31.79%+101.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$29.99-0.9%$27.10$16.10▼$32.14$1.40B1.41489,449 shs547,471 shsCOAGHemab Therapeutics$27.35-4.0%$0.00$23.00▼$36.61$1.28BN/A219,803 shs67,045 shsHROWHarrow$34.96-0.7%$36.03$27.17▼$54.85$1.30B0.28753,365 shs311,717 shsLCTXLineage Cell Therapeutics$1.28-4.1%$1.46$0.65▼$2.09$317.86M1.531.18 million shs687,909 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma0.00%+13.24%-2.64%+30.59%+42.78%COAGHemab Therapeutics0.00%+10.08%-16.18%+2,849,999,900.00%+2,849,999,900.00%HROWHarrow0.00%+6.70%-13.13%-34.30%+24.68%LCTXLineage Cell Therapeutics0.00%+2.31%-11.92%-31.79%+101.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVBPArriVent BioPharma 2.82Moderate Buy$43.3842.30% UpsideCOAGHemab Therapeutics 2.80Moderate Buy$41.7556.95% UpsideHROWHarrow 2.64Moderate Buy$69.4397.21% UpsideLCTXLineage Cell Therapeutics 3.00Buy$6.25382.63% UpsideCurrent Analyst Ratings BreakdownLatest LCTX, AVBP, COAG, and HROW Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026AVBPArriVent BioPharma Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$43.00 ➝ $45.005/27/2026COAGHemab Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/26/2026COAGHemab Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$39.005/26/2026COAGHemab Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.005/26/2026COAGHemab Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$39.005/26/2026COAGHemab Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.005/26/2026COAGHemab Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$50.005/26/2026COAGHemab Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$42.005/22/2026AVBPArriVent BioPharma Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/13/2026HROWHarrow Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$91.00 ➝ $88.005/13/2026AVBPArriVent BioPharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$45.00 ➝ $43.00(Data available from 6/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVBPArriVent BioPharmaN/AN/AN/AN/A$7.44 per shareN/ACOAGHemab TherapeuticsN/AN/AN/AN/AN/AN/AHROWHarrow$272.30M4.82$0.86 per share40.74$1.41 per share24.97LCTXLineage Cell Therapeutics$14.56M22.17N/AN/A$0.19 per share6.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVBPArriVent BioPharma-$166.31M-$3.47N/AN/AN/AN/A-48.98%-45.44%8/10/2026 (Estimated)COAGHemab TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AN/AHROWHarrow-$5.14M-$0.41N/A16.30N/A-5.57%19.59%2.26%8/10/2026 (Estimated)LCTXLineage Cell Therapeutics-$63.53M-$0.12N/AN/AN/A-434.44%-89.36%-36.39%8/11/2026 (Estimated)Latest LCTX, AVBP, COAG, and HROW EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026COAGHemab TherapeuticsN/A-$23.98N/A-$23.98N/AN/A5/12/2026Q1 2026LCTXLineage Cell Therapeutics-$0.02-$0.03-$0.01-$0.03$3.60 million$1.73 million5/11/2026Q1 2026AVBPArriVent BioPharma-$0.88-$0.96-$0.08-$0.96N/AN/A5/11/2026Q1 2026HROWHarrow-$0.43-$0.74-$0.31-$0.74$52.43 million$44.20 million3/5/2026Q4 2025AVBPArriVent BioPharma-$0.87-$0.78+$0.09-$0.78N/AN/A3/5/2026Q4 2025LCTXLineage Cell Therapeutics-$0.07$0.0040+$0.0740$0.0040$1.96 million$6.61 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVBPArriVent BioPharmaN/AN/AN/AN/AN/ACOAGHemab TherapeuticsN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/ALCTXLineage Cell TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVBPArriVent BioPharmaN/A13.9513.95COAGHemab TherapeuticsN/AN/AN/AHROWHarrow10.302.482.30LCTXLineage Cell TherapeuticsN/A6.896.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVBPArriVent BioPharma9.48%COAGHemab TherapeuticsN/AHROWHarrow72.76%LCTXLineage Cell Therapeutics62.47%Insider OwnershipCompanyInsider OwnershipAVBPArriVent BioPharma8.58%COAGHemab TherapeuticsN/AHROWHarrow12.80%LCTXLineage Cell Therapeutics24.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVBPArriVent BioPharma4046.58 million42.58 millionN/ACOAGHemab Therapeutics7246.71 millionN/AN/AHROWHarrow18037.28 million32.50 millionOptionableLCTXLineage Cell Therapeutics60249.30 million187.72 millionNot OptionableLCTX, AVBP, COAG, and HROW HeadlinesRecent News About These CompaniesLineage Cell Therapeutics Q1 Earnings Call HighlightsMay 15, 2026 | marketbeat.comLineage Cell Therapeutics (LCTX) price target increased by 14.58% to 5.61May 14, 2026 | msn.comLineage Cell Therapeutics Inc (LCTX) Q1 2026 Earnings Call Highlights: Strategic Advances and ...May 13, 2026 | finance.yahoo.comLineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2026 Earnings Call TranscriptMay 13, 2026 | insidermonkey.comLineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comLineage Cell (LCTX) Reports Q1 Loss, Lags Revenue EstimatesMay 12, 2026 | zacks.comLineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 12, 2026 | businesswire.comLineage Cell Therapeutics (LCTX) Projected to Post Quarterly Earnings on TuesdayMay 5, 2026 | marketbeat.comLineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026May 5, 2026 | businesswire.comD. Boral Capital Reaffirms Buy Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)May 4, 2026 | marketbeat.comCanaccord Genuity initiates coverage of Lineage Cell Therapeutics (LCTX) with buy recommendationApril 29, 2026 | msn.comLineage Announces Formation of Scientific Advisory BoardApril 13, 2026 | pharmiweb.comPLineage Cell (LCTX) launches its latest cell therapy programMarch 31, 2026 | msn.comLineage Launches New Cell Therapy Program in Corneal Endothelial DiseaseMarch 24, 2026 | finance.yahoo.comLineage Cell Therapeutics (NYSEAMERICAN:LCTX) CEO Purchases $24,300.00 in StockMarch 13, 2026 | insidertrades.comLineage Cell Therapeutics Extends Runway Amid R&D SurgeMarch 7, 2026 | tipranks.comRegulatory Risks Loom for Lineage Cell Therapeutics as Legacy Pluripotent Cell Lines Face Potential Compliance ChallengesMarch 7, 2026 | tipranks.comLineage extends cash runway into Q2 2028 while advancing OpRegen and new pipeline programsMarch 5, 2026 | seekingalpha.comLineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call TranscriptMarch 5, 2026 | seekingalpha.comLineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 5, 2026 | finance.yahoo.comLineage Cell (LCTX) Reports Break-Even Earnings for Q4March 5, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLCTX, AVBP, COAG, and HROW Company DescriptionsArriVent BioPharma NASDAQ:AVBP$29.98 -0.29 (-0.94%) As of 03:06 PM Eastern This is a fair market value price provided by Massive. Learn more.ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.Hemab Therapeutics NASDAQ:COAG$27.35 -1.15 (-4.04%) As of 02:47 PM EasternWe are a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Coagulation disorders encompass a broad and heterogeneous group of conditions, and many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches. Our lead asset, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Our second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. We are also advancing multiple preclinical and discovery-stage assets. We estimate that there are approximately an aggregate of 10,000 patients with Glanzmann thrombasthenia and Factor VII deficiency and an aggregate of 120,000 patients with Von Willebrand Disease in the geographies where we intend to commercialize our assets, including the United States, the European Union, Japan, the Gulf Cooperation Council countries and other select regions. With greater disease burden awareness, potential regulatory approvals of new prophylactic options and expanding global reach of these options, we believe the overall number of addressable patients for our clinical-stage assets, and preclinical and discovery stage programs could be greater than we currently estimate. We aim to establish the industry’s leading coagulation franchise through the execution of our “Hemab 2x3 by 2030” strategic roadmap, which is designed to build a franchise consisting of 2 commercial medicines, 2 new late-stage clinical programs, and 2 new early-stage clinical programs by 2030. We have not yet initiated pivotal trials for any of our product candidates, and due to the novel and unproven nature of our programs, their current stage of development and the lack of approved prophylactic therapies to inform endpoint selection and trial design, we may not be able to achieve our strategic goals on the timeline we expect or at all. Our principal executive offices are located in Cambridge, MA.Harrow NASDAQ:HROW$34.96 -0.25 (-0.72%) As of 03:06 PM Eastern This is a fair market value price provided by Massive. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Lineage Cell Therapeutics NYSEAMERICAN:LCTX$1.27 -0.06 (-4.14%) As of 03:07 PM Eastern This is a fair market value price provided by Massive. Learn more.Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance MarketBeat Week in Review – 05/25 - 05/29 Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17% What Exactly Is Agentic AI, and Why Are Some Stocks Blowing Up Because of It? Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem SanDisk's Stock and Short Interest Both at Record Highs —Do the Bears Know Something? MongoDB's AI Advantage Is Starting to Show Up in Results 3 Ways to Play the Data Center Land Grab Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
